02 December 2017: Articles
Homeopathic Treatment of Vitiligo: A Report of Fourteen Cases
Unusual or unexpected effect of treatment
Seema Mahesh EF 1*, Mahesh Mallappa AB 1, Dionysios Tsintzas CDE 2, George Vithoulkas A 3DOI: 10.12659/AJCR.905340
Am J Case Rep 2017; 18:1276-1283
Abstract
BACKGROUND: Vitiligo, also known as leukoderma, is an autoimmune skin condition that results in the loss of melanin pigment. Vitiligo is not a rare condition but is difficult to treat and is associated with psychological distress.
CASE REPORT: A series of 14 cases of vitiligo are presented that were treated with individualized homeopathic remedies that were based on plant, animal, or mineral compounds. There were 13 women and one man in the case series, with a mean age 29.8 years, and a mean follow-up from treatment of 58 months. The mean time between the onset of the appearance of vitiligo and the first consultation at our clinic was 96 months. Homeopathic treatment for patients is holistic and was performed on an individualized basis as described in this case series. Photographic images of the skin are presented before and after treatment.
CONCLUSIONS: In 14 patients with vitiligo treated with individualized homeopathy, the best results were achieved in the patients who were treated in the early stages of the disease. We believe that homeopathy may be effective in the early stages of vitiligo, but large controlled clinical studies are needed in this area.
Keywords: Autoimmune Diseases, Complementary Therapies, Dermatology, Homeopathy, Vitiligo
Background
Vitiligo is an acquired autoimmune condition that is characterized by the destruction of epidermal melanocytes causing loss of skin pigment [1]. Vitiligo may progress to involve the dermal follicular reserve and to destroy melanocyte stem cells [1]. Although the global prevalence of vitiligo is less than 1%, in some populations, it may be as high as 3% of the population [1]. Classically, vitiligo has been classified into segmental and non-segmental variants, depending on the distribution of skin depigmentation [2]. Vitiligo can cause psychological stress, especially in dark-skinned individuals for whom it causes concerning cosmetic skin changes. Also, in some parts of the world, such as in rural India, vitiligo is considered to be a social stigma, particularly for young girls.
Vitiligo is an autoimmune condition in which multiple immune response genes are believed to be involved [3]. Studies have shown that vitiligo may be caused by a response to oxidative stress, mediated by T-cells and involving mediators such as tumor necrosis factor alpha (TNFα), heat shock protein 70 (Hsp70), and interleukin 1 alpha (IL-1α) [4–6]. Melanocyte destruction is initiated by an imbalance in the production of reactive oxygen species (ROS) that causes free radical damage to the skin melanocytes, leading to protein structural damage, cell apoptosis, activation of cytokines, and damage to cell endoplasmic reticulum (ER) [4–6]. The severity of vitiligo may be assessed by measuring superoxide dismutase, a byproduct of oxidative stress that increases when vitiligo is active but regresses when the lesions become stable [4–6]. Cytokines and chemokines such as C-C chemokine ligand 5 (CCL5), CXC chemokine ligand 12 (CXCL12), interleukin 1 alpha (IL-1α), and tumor necrosis factor alpha (TNFα) have been shown to have a major role in inducing autoantigen presentation and recruitment of antigen-presenting cells (APCs) and activated T-cells and to have a role in destruction of the skin melanocytes, supporting the autoimmune etiology of vitiligo [1,7–11].
Currently, the available treatment options for patients with vitiligo have limited effectiveness, particularly for patients with vitiligo of the acral areas, which are resistant to treatment due to the lack of hair follicles that can serve as reservoirs for melanocytes [1,2]. The criteria for assessing the response to the treatment of vitiligo include: cessation of spread; the appearance of skin re-pigmentation; and overall quality of life during treatment [1,12–14]. However, no therapeutic study has yet shown long-term benefits using these criteria, and further research is required to establish evidence for the effective treatment of vitiligo [1,12–14]. There has been at least one prospective observational clinical study that has investigated the effectiveness of classical homeopathic treatment of vitiligo [15], with a further prospective observational clinical study involving homeopathic treatments given based on characteristic individualized patient symptoms [16,17]. However, to our knowledge, we now report the first retrospective case series describing the long-term effects of the homeopathic treatment of vitiligo.
Case Report
A series of 14 cases of vitiligo are presented that were treated with individualized homeopathic treatments that were based on plant, animal, or mineral compounds (Table 1). There were 13 women and one man in the case series, with a mean age 29.8 years, and a mean follow-up from treatment of 58 months. The mean time between the onset of the appearance of vitiligo and the first consultation at our clinic was 96 months. Homeopathic treatment for patients is holistic and was performed on an individualized basis. Photographic images of the skin are presented before and after treatment (Figures 1–14). All patients were treated were treated according to the laws of classical homeopathy [18,19].
The selection of the homeopathic treatment for these 14 patients was made according to the individual patient symptoms. Initially, each patient was assessed in detail for their psychological and physical symptoms, and the homeopathic treatment was selected for each patient (Table 1). In most 12 out of the 14 cases, more than one homeopathic remedies was prescribed and was used sequentially (Table 1). Patients were followed-up during treatment for a mean time of 58 months. The cases that were treated in the early stages recovered more quickly and completely. However, in other cases, where the skin de-pigmentation had been established for a long period and did not resolve, once the homeopathic treatment began, other health problems improved well while the skin lesion covered very slowly.
Discussion
This retrospective study of a series of 14 cases of vitiligo treated with individualized homeopathic compounds showed that although vitiligo is a primary autoimmune disease of the skin, patients with vitiligo may have involvement of multiple systems of the body. This case series showed that prolonged periods of psychological stress might be involved in the onset and progression of the vitiligo. These associations may support the view that psychological stress and the onset of autoimmune conditions are closely connected [17].
Homeopathic medicine includes a holistic approach to the understanding of the patient and integrates this approach to provide individualized patient treatment [18,19]. Certain diseases may manifest when genetic predisposition combines with stress, and homeopathy recognizes these factors [18]. Homeopathy considers the patient’s susceptibility to certain kind of stress, which means that homeopathy can be more successful during the early development of a disease, even before conventional medicine usually begins [18,19].
The range of action of homeopathic medicine aims to strengthen the action of the immune system through the primary understanding that symptoms are an attempt by the immune system to achieve balance [18,19]. ’Through the application of the principle of resonance, the basis of homeopathic medicine is that if a substance is capable of producing a similar symptom profile in a healthy organism, then the likelihood of its strengthening of the body’s defense mechanisms in a diseased body with the same symptoms is great [18,19]. The fundamental pillar of the science of homeopathy is that ‘like cures like’ [19]. The basis for homeopathy is that any substance (plant, animal, mineral, or metal) that can affect the human health can serve as a medication, when in the right form. Homeopathic medicines are prepared through serial dilutions and using a frictional process called ‘succussion’ or potentization, resulting in no traceable ‘material’ left in the solution, therefore enabling a safe use of toxic substances that may otherwise prove fatal [20]. The symptoms obtained through ‘proving’ of the homeopathic compounds on healthy humans serve as the basis for their prescription in diseased individuals. Because the main therapeutic rule in homeopathy is
The experience of a homeopath treating vitiligo is that the lesions may firstly stop spreading, and existing lesions do not increase in size, and no new lesions appear. Secondly, re-pigmentation may occur, and the borders of the lesions that were formerly diffuse become more clearly marked, indicating cessation of spread. The quality of life for the patient may improve and the symptoms of associated diseases, such as thyroid dysfunction, may also improve [21,22]. These clinical responses to homeopathic treatment in patients with vitiligo may be considered to be an ideal response to treatment [13]. However, for an optimal response to homeopathic treatment to occur, treatment should begin when the body has not suffered the effects of the disease for long and before the immune response becomes irreversible.
In the 14 cases of vitiligo treated with homeopathy and presented in this case series, the longer the time that elapsed between the onset of vitiligo and the homeopathic consultation, the more difficult it was to obtain a good clinical response. The cases of vitiligo that presented in the advanced stages required more homeopathic remedies and in a correct sequence to see clinical change. An explanation of these findings may have been that the health level of the patients had worsened with time and that the immune system needed more stimulation and time to bring about a positive clinical effect on vitiligo [23].
Conclusions
In 14 patients with vitiligo treated with individualized homeopathy, the best results were achieved in the patients who were treated in the early stages of their disease. We believe that homeopathy may be effective in the early stages of vitiligo, but large controlled clinical studies are needed in this area.
References:
1.. Jain A, Mal J, Mehndiratta V, Study of oxidative stress in vitiligo: Indian J Clin Biochem, 2010; 26(1); 78-81, pmid: 22211020
2.. Taieb A, Intrinsic and extrinsic pathomechanisms in vitiligo: Pigment Cell Res, 2000; 13(S8); 41-47, pmid: 11041356
3.. Jin Y, Birlea S, Fain P: New Engl J Med, 2010; 362(18); 1686-97, pmid: 20410501
4.. Alghamdi KM, Khurrum H, Taieb A, Ezzedine K, Treatment of generalized vitiligo with anti-TNF-α agents: J Drugs Dermatol, 2012; 11(4); 534-39, pmid: 22453596
5.. Manga P, Elbuluk N, Orlow SJ, Recent advances in understanding vitiligo: F1000Research, 2016; 5; F1000 Faculty Rev-2234
6.. Eleftheriadou V, Whitton M, Gawkrodger D, Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership: Br J Dermatol, 2011; 164(3); 530-36, pmid: 21128908
7.. Maresca V, Roccella M, Roccella F, Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo: J Invest Dermatol, 1997; 109(3); 310-13, pmid: 9284096
8.. Rezk A, Kemp D, El-Domyati M, Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression: J Invest Dermatol, 2017; 137(5); 1126-34, pmid: 28132854
9.. Yang L, Wei Y, Sun Y, Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo: Acta Derm Venereol, 2015; 95(6); 664-70, pmid: 25721262
10.. Xie H, Zhou F, Liu L, Vitiligo: How do oxidative stress-induced auto-antigens trigger autoimmunity?: J Dermatol Sci, 2016; 81(1); 3-9, pmid: 26387449
11.. Singh M, Shoab Mansuri M, Parasrampuria MA, Begum R, Interleukin 1-α: A modulator of melanocyte homeostasis in vitiligo: Biochem Anal Biochem, 2016; 5; 2
12.. Whitton M, Pinart M, Batchelor J, Interventions for vitiligo.: Cochrane Database Syst Rev, 2015(2); CD003263, pmid: 25710794
13.. Parsad D, A new era of vitiligo research and treatment: J Cutaneous Aesthetic Surg, 2013; 6(2); 63-64
14.. Alsubait N, Mulekar S, Al Issa A, Failure of non-cultured melanocyte – keratinocyte transplantation in periungual vitiligo: A case report: J Dermatol Dermatol Surg, 2015; 19(2); 123-25
15.. Ganguly S, Saha S, Koley M, Mondal R, Homeopathic treatment of vitiligo: An open observational pilot study: Int J High Dilution Res, 2013; 12(45); 168-77
16.. Swami S, Dasgupta S, Basu S, Swarnakar G, Significant remission of vitiligo by ultradiluted alternative medicines: Asian Journal of Pharmaceutical Clinical Research, 2012; 5(2); 33-35
17.. Trapp E, Trapp M, Sampogna F, Autonomic nervous tone in vitiligo patients – a case-control study: Acta Derm Venereol, 2015; 95(2); 169-72, pmid: 24820126
18.. Vithoulkas G, Carlino S, The “continuum” of a unified theory of diseases: Med Sci Monit, 2010; 16(2); SR7-15, pmid: 20110932
19.. Vithoulkas G, The basic principles of homeopathy: Homeopathy: The Energy Medicine, 2013, Athens, International Academy of Classical Homeopathy
20.. Vithoulkas G: The science of homeopathy, 1980; 91-92, New York, Grove Press
21.. van Geel N, Speeckaert M, Brochez L, Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases: J Eur Acad Dermatol Venereol, 2013; 28(6); 741-46, pmid: 23590677
22.. Xianfeng C, Yuegen J, Zhiyu Y, Pediatric patients with vitiligo in Eastern China: Abnormalities in 145 cases based on thyroid function tests and immunological findings: Med Sci Monit, 2015; 21; 3216-21, pmid: 26496247
23.. Vithoulkas G, Woensel E: Levels of health., 2010, Alonissos, Greece, International Academy of Classical Homeopathy
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






